Eli Lilly to buy Centessa Pharmaceuticals for $7.8 billion

Eli Lilly & Co. has agreed to acquire Centessa Pharmaceuticals Plc in a deal potentially worth up to $7.8 billion. This acquisition aims to expand Eli Lilly's existing portfolio, particularly into treatments for sleep disorders. The move signifies a strategic expansion for the pharmaceutical giant, known for its work in obesity treatments. The acquisition is expected to enhance Eli Lilly's therapeutic offerings and market reach in new medical areas.